Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
archives
»
Monthly Archive
» March 2012
March 2012
Sanofi eyes 40 pct of sales from emerging mkts -CEO
Sanofi eyes 40 pct of sales from emerging mkts -CEO
Reuters
Sanofi
emerging markets
Pharma CEOs
Chris Viehbacher
AstraZeneca: U.S. ruling over Seroquel favorable
AstraZeneca: U.S. ruling over Seroquel favorable
Marketwatch
Seroquel XR
AstraZeneca
patents
Mylan
Torrent Pharmaceuticals
MAP Pharma falls on 4Q loss and restatement
MAP Pharma falls on 4Q loss and restatement
Yahoo/AP
MAP Pharmaceuticals
earnings
How Much Further Can Rare Diseases Carry BioMarin?
How Much Further Can Rare Diseases Carry BioMarin?
Seeking Alpha
Biomarin
Amicus Therapeutics
Sanofi
Vertex
Will Obesity Drugs Do Better in Europe?
Will Obesity Drugs Do Better in Europe?
Motley Fool
obsesity
Arena
Vivus
Orexigen
lorcaserin
Contrave
Qnexa
Discovery Laboratories posts smaller 4th-qtr loss on lower expenses, stock-related gain
Discovery Laboratories posts smaller 4th-qtr loss on lower expenses, stock-related gain
Yahoo/AP
earnings
Discovery Labs
Judge denies AZ's bid to stop Seroquel copies, but chides FDA
Judge denies AZ's bid to stop Seroquel copies, but chides FDA
Fierce Pharma
FDA
Seroquel
generics
AstraZeneca
Teva Pharmaceuticals
Mylan
FDA extends review period for Forest Lab lung drug
FDA extends review period for Forest Lab lung drug
Reuters
COPD
Forest Labs
FDA
Almirall
Breathe Easy: Relovair Program Complete, Data Solid
Breathe Easy: Relovair Program Complete, Data Solid
Motley Fool
Relovair
GSK
Theravance
Advair
GlaxoSmithKline: A Solid Dividend Pick For 2012
GlaxoSmithKline: A Solid Dividend Pick For 2012
Seeking Alpha
GSK
Abbott Laboratories
JNJ
dividends
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »